Transforming the treatment of diabetes using next generation human iPSC-based regenerative medicine technologies
Who We Are
BetaLife is a stem cell therapy company that is focused on regenerative medicine for diabetes. We are founded by a team of passionate expert scientists with over a decade of experience and track record in diabetes and stem cell research. We are backed by a network of established clinicians and innovators in the diabetes and organ transplant field.
What We Do
BetaLife is developing pancreatic islet cells with superior functionality from high quality, clinical-grade human induced pluripotent stem cells (hiPSCs) for cell replacement therapy. Our goal is to leverage on our hiPSC platform to generate off-the-shelf islet cells to provide a better life for diabetes patients. Our hiPSC platform has the potential to be capitalised for multiple clinical indications in the future.